Phase II Trial in Platinum-refractory Ovarian Cancer: A Randomized Multicenter Trial With SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy
Phase of Trial: Phase II
Latest Information Update: 05 May 2014
At a glance
- Drugs Sunitinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 21 Jul 2012 Actual end date (5 Jun 2012) added as reported by European Clinical Trials Database.
- 29 Feb 2012 Results published in Annals of Oncology.
- 30 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.